A 42-year-old man with dilated cardiomyopathy and endstage heart failure was evaluated for heart transplantation. He received a MitraClip and Carillon annuloplasty device for functional mitral regurgitation as palliation for his heart failure. Subsequently, he underwent successful heart transplantation.
Introduction
Patients with endstage heart failure develop functional mitral regurgitation (FMR) as a consequence of distorted left ventricular geometry. Reducing the severity of FMR in these patients has been shown to improve their quality of life while waiting for a transplant. 1, 2 Several catheter-based devices, such as the MitraClip and Carillon Mitral Contour System, have been developed as alternatives to surgical correction of FMR. We describe a case of successful heart transplantation for dilated cardiomyopathy and endstage heart failure in which a MitraClip and Carillon device were utilized as bridging therapy.
Case report
A 42-year-old gentleman presented with severe breathlessness and ascites. He had been diagnosed with nonischemic cardiomyopathy with severe mitral regurgitation 5 years earlier. In view of his worsening heart failure with frequent hospitalizations, he was listed for cardiac transplantation. He had undergone percutaneous implantation of a MitraClip (Abbott Vascular, Santa Clara CA, USA) to correct FMR 3 years later (Figure 1 ). There was a 20% reduction in the B-type natriuretic peptide level 3 weeks after this procedure. Subsequently, he received an implantable cardioverter defibrillator. An increase in left ventricular ejection fraction by 6%-8% was observed, with an improvement in functional class for 3 months. However, the patient deteriorated with recurrence of significant mitral regurgitation and he underwent implantation of a Carillon Mitral Contour System (Cardiac Dimensions, Kirkland, WA, USA; Figure 2 ). Although there was reduction in FMR by 1 grade, and improvement in functional class, requiring no inotropic support for 3 months, he deteriorated again over a period of 8 months. All the aforementioned procedures were carried out in overseas institutions, and he was referred to us for cardiac transplantation. He presented with worsening symptoms in INTERMACS profile 2 advanced heart failure. Peritoneal tapping was performed twice to relieve his ascites. The option of a left ventricular assist device was discussed with his relatives. In the meantime, with the availability of a matching donor and the patient being relatively stable, he underwent heart transplantation at our center. Tripleimmunosuppressant therapy was started. He required peritoneal tapping for massive ascites in the immediate postoperative period. He was discharged on 13th postoperative day. At the 3-month and 1-year follow-up examinations, he was doing well clinically and had no postoperative complications. Endomyocardial biopsy at 1 year showed no signs of rejection.
Discussion
Cardiac transplantation is the most effective therapeutic option for patients with endstage heart failure. Apart from pharmacological measures, several palliative bridging therapies, including catheter-based devices, have been implemented during the waiting period. The primary goal is to improve the general condition of the patient by reducing FMR, increasing afterload, and preventing sustained ventricular arrhythmias. Several transcatheter devices have been developed for repair of the mitral valve. The MitraClip is one such novel device based on the principle of edge-to-edge surgical mitral valve repair. The Carillon Mitral Contour System is another well-known percutaneous annuloplasty device used as alternative therapy for FMR. It comprises a nitinol clip implanted in the coronary sinus, which reduces the posterolateral aspect of mitral annular dimension, reducing mitral regurgitation. These devices have gained popularity in achieving mitral valve competency without an additional surgical procedure. The recent EVEREST II randomized controlled trial compared outcomes of the MitraClip and surgical mitral valve repair, and demonstrated superior safety with the MitraClip and similar symptomatic improvement in patients. The impact of the Carillon device on FMR in patients with heart failure was assessed in the TITAN trial that found significant clinical improvement with reverse left ventricular remodeling at 24 months. [2] [3] [4] However, Whitlow and colleagues 4 studied the efficacy of the MitraClip in a high-risk group of patients and noted a high procedure-related mortality of 8%. The EVEREST II trial recorded a 46% incidence of persistent mitral regurgitation at 1 year.
There are some reports of patients with endstage heart failure having heart transplantation after these percutaneous procedures. Garatti and colleagues 1 described one patient who received a MitraClip as a bridge to heart transplantation. Schofer and colleagues 5 had one patient who underwent cardiac transplantation after a Carillon device was implanted. This patient had 3 catheter-based interventions: MitraClip and Carillon devices to reduce FMR, and an implantable cardiac defibrillator to abolish interventricular dyssynchrony and optimize ventricular contraction. These procedures were delivered as a mode of palliation until the availability of a matching donor. Similarly, in our patient, both MitraClip and Carillon devices were inserted as a bridge to transplantation.
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